Last updated: April 23, 2026
Summary: Proparacaine hydrochloride (CAS 5875-04-5) is supplied by a mix of API and specialty-chemical manufacturers. The supplier set used by formulators generally splits into (1) regulated API producers and (2) chemical intermediates/specialty suppliers that sell bulk material under documentation packages (CoA, typical spec sheets, and shipping-ledger traceability). The market also includes distributors who consolidate inventory from multiple API makers.
Who supplies proparacaine hydrochloride (API) in bulk?
The most common channels in the proparacaine hydrochloride supply chain are:
API manufacturers (direct bulk supply)
These suppliers typically list proparacaine hydrochloride as a finished API grade or as “USP/EP-type” material, with batch documentation (CoA), impurity spec frameworks, and controlled sourcing.
Specialty chemical suppliers (bulk, non-pharma grade to pharma-grade)
These suppliers often provide multiple grades (research grade vs. pharma grade) and market documentation packages aligned to regulatory readiness, depending on the listing.
Distributors (consolidated inventory)
Distributors usually do not manufacture the API. They provide procurement convenience, lead-time smoothing, and multiple sourcing options.
Contract manufacturers and custom synthesis providers (shortfall coverage)
For supply continuity, some buyers use custom synthesis and finishing services when standard inventory tightens or impurity control requirements change.
What supplier types matter for regulated drug development and commercialization?
For proparacaine hydrochloride intended for use in finished dosage forms (ophthalmic or topical anesthetic products), procurement is typically constrained by:
- Quality system maturity (GMP manufacturing and batch release controls if API is for drug product use)
- Impurity profile documentation (CoA-driven release plus realistic impurity thresholds tied to the target monograph and process capability)
- Regulatory alignment (DMF/EDMF availability where applicable; or at minimum, consistent pharma-grade spec and auditability)
- Supply continuity (number of qualified suppliers and substitution risk)
Where is proparacaine hydrochloride sourced from globally?
Supply is typically global, with sourcing concentrated in jurisdictions that host:
- Bulk chemical manufacture for pharmaceutical actives
- Ophthalmic API and fine-chemical production clusters
- Regional distributors that stock small-to-mid bulk quantities
Procurement structures commonly run:
- Direct import from API manufacturers
- Distributor purchase for batch economics and shorter lead times
- Dual sourcing for continuity
How suppliers are usually positioned in the market
API listing formats you will see
Most suppliers position proparacaine hydrochloride using one or more of these identifiers:
- CAS: 5875-04-5
- Hydrochloride salt form (proparacaine HCl)
- Grade tags (USP/EP/JP-type, pharmaceutical grade, research grade)
- Package sizes (typical bulk: tens of grams to multi-kilograms; commercial lots depend on the supplier)
Documentation packages that buyers typically receive
Procurement of pharma-intended material commonly expects:
- CoA per lot
- Specification sheet (assay, identity, impurities, water content if specified, residue on ignition)
- Analytical methods summary (sometimes on request)
- GMP statements (for GMP-manufactured lots, where applicable)
- SDS and traceability documentation
Supplier short list: what to check before qualification
The qualification process for proparacaine hydrochloride generally focuses on:
- Salt form correctness: “proparacaine hydrochloride” vs. related free base listings
- Impurities: consistency of minor components across lots (key for stability and release)
- Assay and particle/handling attributes if relevant for formulation performance
- Batch size and lead time aligned to your campaign schedule
- Regulatory documentation: DMF/EDMF availability or audit-readiness
Key procurement facts that determine supplier choice
Regulatory and product use
Proparacaine hydrochloride is widely used as a topical local anesthetic (commonly ophthalmic). This creates a strong preference for:
- Pharmaceutical-grade API
- Traceable controlled manufacturing
- CoA consistency and impurity governance
Practical selection criteria
Buyers typically evaluate suppliers on:
- Ability to supply the required lot size
- Stability/consistency of CoA trend lines
- Responsiveness on change notifications
- Contract terms (lead time, minimum order quantity, lot splitting policies)
Market-facing supplier categories you can operationalize
Because “supplier” in this market can mean manufacturer or distributor, operational procurement normally uses two parallel tracks:
- Qualified API manufacturer track
- For regulatory filing continuity and consistent impurity profile
- Alternate supply track (distributor or second manufacturer)
- For continuity under lead-time shocks
Key Takeaways
- Proparacaine hydrochloride supply typically comes from API manufacturers, specialty chemical suppliers, and distributors.
- For drug product use, supplier qualification is dominated by impurity control, pharma-grade documentation, and batch-to-batch CoA consistency.
- Operational procurement usually uses dual sourcing (one primary API manufacturer plus an alternate channel) to manage lead-time and continuity risk.
FAQs
Which supplier type is best for regulated drug product manufacturing?
An API manufacturer with pharma-grade documentation and auditability is typically the preferred route for regulatory-facing production runs.
How do buyers verify the material is the correct salt?
They verify CAS (5875-04-5) plus supplier labeling of the hydrochloride salt form, and they confirm identity testing in the CoA (and method where required).
What documentation should appear on the CoA for proparacaine hydrochloride?
At minimum: assay, identity, and impurities consistent with the supplier’s pharma-grade spec; plus lot traceability and test method identifiers.
What drives impurity risk in proparacaine hydrochloride sourcing?
Impurity risk comes from process differences, raw material sourcing, and controls on reaction and salt formation, which show up as different minor component patterns across lots.
Is distributor sourcing acceptable if the API grade is correct?
Distributor sourcing can work for continuity, but it still hinges on receiving pharma-grade documentation and ensuring the material maps to your spec and impurity expectations for the intended regulatory use.
References
- PubChem. “Proparacaine Hydrochloride.” PubChem Compound Summary. https://pubchem.ncbi.nlm.nih.gov/compound/Proparacaine-Hydrochloride
